An exosome-related six-gene signature was developed to stratify gastric cancer risk and identify oncogenic drivers, with the work also confirming DCBLD2 and GPC3 as cellular drivers. The model aims to translate extracellular vesicle biology into clinically usable prognostic and mechanistic insights. Because exosomes can carry disease-relevant molecular cargo, multi-gene signatures may improve risk discrimination compared with single markers, though external validation details are key for clinical translation. For translational teams, the main value is the coupling of stratification with driver confirmation, which can inform future therapeutic targeting and patient selection frameworks.